Latest news with #PatrickWood
Business Insider
29-05-2025
- Business
- Business Insider
Morgan Stanley Sticks to Its Hold Rating for GE Healthcare Technologies Inc (GEHC)
In a report released yesterday, Patrick Wood from Morgan Stanley maintained a Hold rating on GE Healthcare Technologies Inc (GEHC – Research Report), with a price target of $78.00. The company's shares closed yesterday at $67.09. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Wood covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Baxter International, and Cooper Co. According to TipRanks, Wood has an average return of -1.0% and a 50.00% success rate on recommended stocks. In addition to Morgan Stanley, GE Healthcare Technologies Inc also received a Hold from UBS's Graham Doyle in a report issued on May 5. However, on May 1, Goldman Sachs maintained a Buy rating on GE Healthcare Technologies Inc (NASDAQ: GEHC). The company has a one-year high of $94.80 and a one-year low of $57.65. Currently, GE Healthcare Technologies Inc has an average volume of 4.81M. Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GEHC in relation to earlier this year. Most recently, in February 2025, George A. Newcomb, the CAO of GEHC sold 2,000.00 shares for a total of $185,080.00.
Business Insider
06-05-2025
- Business
- Business Insider
Baxter International (BAX) Receives a Sell from Morgan Stanley
In a report released yesterday, Patrick Wood from Morgan Stanley maintained a Sell rating on Baxter International (BAX – Research Report), with a price target of $28.00. The company's shares closed yesterday at $30.43. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Wood covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Baxter International, and Cooper Co. According to TipRanks, Wood has an average return of -1.0% and a 50.00% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baxter International with a $37.27 average price target. BAX market cap is currently $15.75B and has a P/E ratio of -27.94.
Yahoo
04-05-2025
- Business
- Yahoo
Prediction: 2 Stocks Will Be Worth More Than Palantir Technologies in 2026
Palantir is currently worth $269 billion, but certain Wall Street analysts think Intuitive Surgical and ServiceNow can top that figure in 2026. ServiceNow is a leader in IT service management and IT operations software, and recently released AI products are driving revenue growth. Intuitive Surgical is a technology leader in robotics-assisted surgical systems, and it recently won new approvals from the FDA. Palantir Technologies is currently worth $269 billion. But these Wall Street analysts think Intuitive Surgical (NASDAQ: ISRG) and ServiceNow (NYSE: NOW) can top that figure in 2026: Patrick Wood at Morgan Stanley has set Intuitive Surgical with a bull-case target price of $850 per share. That implies 64% upside from its current share price of $517. It also implies a market value of $304 billion. Patrick Walravens at JMP Securities has set ServiceNow at a target price of $1,300 per share. That implies 36% upside from its current share price of $955. It also implies a market value of $270 billion. Here's what investors should know about these stocks. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Intuitive Surgical is the leader in robotics-assisted surgery. It is best known for its da Vinci systems, which let surgeons perform minimally invasive procedures with greater precision in five areas: General surgery Urologic surgery Gynecologic surgery Cardiothoracic surgery Head and neck surgery The company also provides Ion systems for minimally invasive lung biopsies. Importantly, Intuitive has a razor-and-blade business model. Surgical and diagnostic systems are the razors; they represent significant but infrequent expenses for healthcare facilities. And the adjacent instruments and accessories are the blades; they include consumable tools like scalpels and forceps that must be replaced with each procedure. The razor-and-blade model creates a steady revenue stream. Intuitive Surgical reported strong first-quarter financial results that beat estimates on the top and bottom lines. Revenue rose 19% to $2.2 billion on strong growth in da Vinci procedures and system placements. Meanwhile, non-GAAP (generally accepted accounting principles) earnings rose 21% to $1.50 per diluted share. Intuitive is well positioned to keep its momentum. Recently, the company won approvals from the Food and Drug Administration that let da Vinci systems perform more colorectal surgical procedures. In a note to clients, Morgan Stanley analyst Patrick Wood said the total addressable market is "larger than investors might appreciate." So, the new approval could lead to faster-than-expected growth in the coming quarters. Wall Street says adjusted earnings will increase 10% annually through 2026, but analysts have often missed the mark. Intuitive Surgical beat the consensus estimate by an average of 14% in the last four quarters. If earnings grow at 28% annually -- equal to growth in 2024 -- through the third quarter of 2026, its market value could reach $270 billion without any change in the price-to-earnings (P/E) ratio. However, Intuitive shares currently trade at 68 times earnings, an expensive valuation for a company forecast to grow earnings at 10% annually. So, my prediction is admittedly a long shot. The company would need a series of very strong financial results to top Palantir's current market value in 2026, and the bull-case target set by Morgan Stanley seems unlikely. Regardless, patient investors should consider buying a small position in this robotics stock today. ServiceNow provides workflow management software that helps businesses organize and digitize processes across departments. Its core competency is IT software. It is the market leader in IT service management and artificial intelligence (AI) for IT operations software. Importantly, the company added generative AI features called Now Assist in 2023, and agentic AI capabilities in 2025. ServiceNow reported solid financial results in the first quarter, beating estimates on the top and bottom lines. Revenue increased 18% to $3 billion, and non-GAAP net income increased 18% to $4.04 per diluted share. "ServiceNow's position as the platinum standard for enterprise-grade AI drove these outstanding first-quarter results," CEO Bill McDermott told analysts. "The software industrial complex is converging on ServiceNow as the AI operating system for the enterprise." Wall Street expects ServiceNow's adjusted earnings to grow at 19% annually through 2026, but the company beat the consensus estimate by an average of 7% over the last six quarters. If that trend persists through the third quarter of 2026, trailing-12-month earnings would hit $20.10 per share. If ServiceNow keeps its current valuation of 66 times earnings, its share price would hit $1,325, implying 39% upside from the current price. In that scenario, ServiceNow would hit a market value of $275 billion after reporting third-quarter financial results in 2026, more than Palantir is worth today. However, the current valuation is expensive for a company forecast to grow earnings at 19% annually, which means ServiceNow needs flawless execution to hit that mark. Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $611,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $684,068!* Now, it's worth noting Stock Advisor's total average return is 889% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Trevor Jennewine has positions in Palantir Technologies. The Motley Fool has positions in and recommends Intuitive Surgical, Palantir Technologies, and ServiceNow. The Motley Fool has a disclosure policy. Prediction: 2 Stocks Will Be Worth More Than Palantir Technologies in 2026 was originally published by The Motley Fool
Globe and Mail
03-04-2025
- Business
- Globe and Mail
DelphX Capital Markets Provides Update on CRS Program and Expands Broker-Dealer Services to Include Private Placements for Mid-Market Companies
Toronto, Ontario--(Newsfile Corp. - April 3, 2025) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) (" DelphX" or " the Company"), a leader in the development of new classes of structured products for the fixed income market, wishes to update investors on the advancements in its Credit Rating Security ("CRS") program. As the merits of the CRS solution becomes more widely recognized, the Company has been able to expand both potential buyers and sellers of CRS to now include three leading hedge funds and two insurance companies, who together are negotiating terms to the first groupings of bonds which will be referenced in these first issuances. In a list of over 30 bonds being reviewed the Company expects transactions in CRS to be finalized in Q2 2025. Positive reception from hedge funds and institutional buyers underscores the potential for CRS to become a significant risk management tool. Under normal circumstances the Company expects to receive fees of USD $100,000 or more on each bond under which a CRS is issued. The Company also wishes to announce the expansion of its broker-dealer services to include private placement business across all credit market products. This strategic initiative leverages DelphX's expertise in structured products and credit risk management to deliver innovative funding solutions tailored to mid-market companies. It also follows the requests from hedge funds to provide new lines of investment opportunities which are currently not being presented. Under no circumstances will this expansion infringe on the CRS program or any of its strategic initiatives. "Based on demand from hedge funds and others who seek new investment opportunities, we are excited to broaden our broker-dealer capabilities to include private placements, targeting mid-market companies with unique financing needs," said Patrick Wood, President and CEO of DelphX Capital Markets Inc. "Our team's experience in bond markets, combined with strategic partnerships, enables us to connect growing corporations with capital efficiently and without harm to our primary focus of Credit Rating Securities. This expansion reinforces our commitment to innovation and value creation in the credit markets and further enhances revenue opportunities for the Company." About DelphX Capital Markets Inc. DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle Quantem LLC, the Company enables fixed income dealers to offer new private placement securities that provide mitigation of spread and capital charge losses when downgrades occur, while allowing for attractive returns. The new DelphX securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in: Collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds; Collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade exposure of an underlying security in exchange for attractive returns. All CPOs and CRNs are fully collateralized and held in custody by US Bank. CPOs and CRNs are proprietary products created and owned by DelphX Capital Markets. For more information about DelphX, please visit Contact: George Wentworth, General Manager DelphX Capital Markets Inc. (718) 509-2160 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Yahoo
03-04-2025
- Business
- Yahoo
DelphX Capital Markets Provides Update on CRS Program and Expands Broker-Dealer Services to Include Private Placements for Mid-Market Companies
Toronto, Ontario--(Newsfile Corp. - April 3, 2025) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX" or "the Company"), a leader in the development of new classes of structured products for the fixed income market, wishes to update investors on the advancements in its Credit Rating Security ("CRS") program. As the merits of the CRS solution becomes more widely recognized, the Company has been able to expand both potential buyers and sellers of CRS to now include three leading hedge funds and two insurance companies, who together are negotiating terms to the first groupings of bonds which will be referenced in these first issuances. In a list of over 30 bonds being reviewed the Company expects transactions in CRS to be finalized in Q2 2025. Positive reception from hedge funds and institutional buyers underscores the potential for CRS to become a significant risk management tool. Under normal circumstances the Company expects to receive fees of USD $100,000 or more on each bond under which a CRS is issued. The Company also wishes to announce the expansion of its broker-dealer services to include private placement business across all credit market products. This strategic initiative leverages DelphX's expertise in structured products and credit risk management to deliver innovative funding solutions tailored to mid-market companies. It also follows the requests from hedge funds to provide new lines of investment opportunities which are currently not being presented. Under no circumstances will this expansion infringe on the CRS program or any of its strategic initiatives. "Based on demand from hedge funds and others who seek new investment opportunities, we are excited to broaden our broker-dealer capabilities to include private placements, targeting mid-market companies with unique financing needs," said Patrick Wood, President and CEO of DelphX Capital Markets Inc. "Our team's experience in bond markets, combined with strategic partnerships, enables us to connect growing corporations with capital efficiently and without harm to our primary focus of Credit Rating Securities. This expansion reinforces our commitment to innovation and value creation in the credit markets and further enhances revenue opportunities for the Company." About DelphX Capital Markets Inc. DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle Quantem LLC, the Company enables fixed income dealers to offer new private placement securities that provide mitigation of spread and capital charge losses when downgrades occur, while allowing for attractive returns. The new DelphX securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in: Collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds; Collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade exposure of an underlying security in exchange for attractive returns. All CPOs and CRNs are fully collateralized and held in custody by US Bank. CPOs and CRNs are proprietary products created and owned by DelphX Capital Markets. For more information about DelphX, please visit Contact: George Wentworth, General ManagerDelphX Capital Markets 509-2160 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
